Medically reviewed by Charles Maddix, MSN, APRN, PMHNP-BC
Last updated: July 2026

DoxyPEP for Women: What the Kenya Trial Means — and What It Doesn't

If you've read that DoxyPEP "doesn't work for women," you've heard a half-truth. One major trial in women found no protection, and that result is real. But the most likely explanation is not that female biology defeats doxycycline — it's that most participants weren't actually taking the pills. Here's what the evidence shows, what it doesn't, and what CDC guidance currently says for cisgender women.

What the Kenya trial actually did

The dPEP Kenya study, published in the New England Journal of Medicine in late 2023, was the first randomized trial of DoxyPEP in cisgender women. It enrolled several hundred Kenyan women aged 18 to 30 who were already taking daily HIV PrEP. Half were assigned to take 200 mg of doxycycline within 72 hours after sex, the same protocol used in the DoxyPEP studies in men. Half got standard care. Everyone was tested quarterly for chlamydia, gonorrhea, and syphilis for a year.

The result: STI rates were statistically indistinguishable between the two groups. Taken at face value, DoxyPEP did nothing. That's the finding behind every "DoxyPEP fails in women" headline.

Why the result is more complicated than the headline

The adherence problem. The trial included an objective check most studies skip: hair samples analyzed for doxycycline. Only a minority of samples from the DoxyPEP group had detectable drug — meaning most participants assigned to DoxyPEP were, by biological evidence, not taking it consistently. A prevention pill can't work if it isn't taken. This doesn't make the trial useless; it means the trial mostly measured what happens when DoxyPEP is prescribed in that setting, not what happens when it's used as directed.

The resistance problem. In the region where the trial ran, surveillance shows the overwhelming majority of gonorrhea strains already carry tetracycline resistance. DoxyPEP's gonorrhea protection was always its weakest claim — even in US men, gonorrhea protection erodes wherever resistant strains dominate — so a null result for gonorrhea in Kenya was close to preordained. Chlamydia and syphilis are a different question, and that's where the adherence gap matters most.

The biology question. Some researchers have asked whether doxycycline concentrates well enough in cervical and vaginal tissue to stop an infection taking hold there, since the male trials involved mostly rectal and urethral exposures. Doxycycline does reach the female genital tract — it's used to treat pelvic infections — but whether a single 200 mg post-exposure dose reaches protective levels at that site fast enough is genuinely unsettled. It's a real open question, not a proven barrier.

What CDC guidance says for women right now

CDC's DoxyPEP guidance recommends offering it to gay and bisexual men and transgender women who've had a bacterial STI in the past 12 months. For cisgender women, CDC guidance makes no recommendation either way: the agency's position is that there isn't yet evidence showing benefit in women, and the one completed trial was negative. That's an evidence gap, not a verdict. CDC has been explicit that more research in women is needed, and studies designed to answer the adherence and tissue-level questions are in progress.

Does this mean women should never use DoxyPEP?

No — it means the decision sits in a gray zone that deserves a real clinician conversation rather than a blanket yes or no. Points that matter in that conversation:

• Your STI history. The case is strongest for women with repeated chlamydia or syphilis diagnoses, where the potential benefit is concrete rather than theoretical.
• Which infections you're trying to prevent. Expecting meaningful gonorrhea protection is not realistic anywhere resistance is common. Chlamydia and syphilis are the plausible wins.
• Adherence honesty. The regimen only has a chance if the dose actually gets taken within 72 hours after sex, every time. If that's not realistic for your life, the Kenya result is a preview.
• Side effects and interactions. Doxycycline's side effect profile is the same for everyone — stomach upset, sun sensitivity, esophageal irritation — and none of it is specific to women, but it belongs in the math.

Some US clinicians do prescribe DoxyPEP to cisgender women off-guideline after exactly this kind of discussion. That's a legitimate shared decision, as long as nobody pretends the evidence is stronger than it is.

What this means for you

If you're a woman weighing DoxyPEP: the honest summary is that it has not been shown to work in women, it also hasn't been shown to fail when actually taken, and the strongest trial we have mostly measured non-use. Your baseline prevention toolkit — condoms, PrEP if HIV exposure is a possibility, and quarterly STI testing — doesn't have that ambiguity attached. If repeat bacterial STIs are part of your reality, raise DoxyPEP directly with a prescriber, ask them to walk through the Kenya trial's limitations with you, and make the call together. A telehealth visit is a reasonable place to have that conversation.

Go deeper